Methods and devices to regulate stem cell homing

• US 8,636,995 B2
• Filed: 08/31/2006
• Issued: 01/28/2014
• Est. Priority Date: 08/31/2006
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Stolen, Craig
• Primary Examiner(s): Long, Scott
• Application Number:
  US11/469,092
• Publication Number:
  US 20080057027A1
• Time in Patent Office: 2,707 Days
• Field of Search: None
• US Class Current: 424/85.1
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons

Abstract

A device for altering the expression or activation of adhesion molecules on cells including endothelial cells, as well as methods for altering the expression or activation of adhesion molecules on cells including endothelial cells, are provided.

Claims

1. A device adapted to deliver donor cells with enhanced localization to host tissue including endothelial cells in a body, comprising:

an implantable delivery device configured to deliver the donor cells to the lumen of a vessel in the body and having a lumen with a surface portion including activated endothelium applied to the surface portion which has ridges configured to promote interaction between the activated endothelium and the donor cells so as to enhance the localization, extravasation, or both, of the donor cells by activating adhesion molecules on the donor cells or increasing expression of adhesion molecules on the donor cells relative to donor cells in the absence of the activated endothelium and ridges.

2. The device of claim 1 wherein the activated endothelium activates adhesion molecules on donor cells administered via the device.

3. The device of claim 1 wherein the activated endothelium increases expression of adhesion molecules on donor cells administered via the device.

4. The device of claim 1 wherein the implantable device comprises a percutaneous injection device comprising a catheter configured to allow injection of donor cells via the lumen having the surface portion.

19. The device of claim 1 wherein one of the one or more agents applied to the surface portion is a cytokine.

20. The device of claim 1 wherein the one or more agents are applied to the surface portion via a linker.

5. A device for treating hematopoietic donor cells used in cell therapy, comprising:

a surface portion; and

an activation surface including different agents applied to the surface portion, wherein the different agents increase expression or activation of adhesion molecules on hematopoietic donor cells, the activation surface having ridges configured to promote interaction between the different agents and the hematopoietic donor cells as the hematopoietic donor cells contact the activation surface, wherein the activation surface comprises a plurality of activation surface regions each including one or more of the different agents, and wherein the activation surface regions are arranged to allow the hematopoietic donor cells to contact each of the activation surface regions with the different agents in a predetermined order to allow multiple steps of activation according to a predetermined activation sequence selected so as to increase expression or activated adhesion molecules including LFA-1 or Mac-1 on the hematopoietic donor cells.

6. The device of claim 5 comprising a container including the surface portion, the container containing the hematopoietic donor cells.

7. The device of claim 6 wherein the container comprises a dish including a bottom portion being the surface portion.

8. The device of claim 6 wherein the container comprises a circular tube having an interior wall to enclose the hematopoietic donor cells, at least a portion of the interior wall being the surface portion.

9. The device of claim 6 comprising a rocker coupled to the container, the rocker adapted to create a motion of the container that causes the hematopoietic donor cells to contact the surface.

10. The device of claim 9 comprising a motion controller coupled to the rocker, the motion controller adapted to control the motion of the container and including:

a velocity controller to control a velocity of the motion of the container; and

a pattern controller to control a pattern of the motion of the container.

11. The device of claim 5 comprising an elongate tube including a lumen configured to allow passage of the hematopoietic donor cells, at least a portion of the lumen including the surface portion.

12. The device of claim 11 comprising an injection device configured to deliver the hematopoietic donor cells in the cell therapy, the injection device including the elongate tube.

13. The device of claim 11 comprising:

a pump coupled to the elongate tube, the pump adapted to pump the hematopoietic donor cells through the lumen; and

a pump controller coupled to the pump, the pump controller adapted to control a speed of the passage of the hematopoietic donor cells through the lumen.

14. The device of claim 5 comprising a fluid circulating system including:

a container to contain the hematopoietic donor cells in a fluid; and

a circulation pathway configured to allow passage of the hematopoietic donor cells and the fluid, the circulation pathway including;

an entrance to allow the hematopoietic donor cells and the fluid to enter the circulation pathway from the container;

an exit to allow the hematopoietic donor cells and the fluid to return to the container from the circulation pathway;

a pump between the entrance and the exit, the pump adapted to pump the hematopoietic donor cells and the liquid through the circulation pathway; and

the surface portion between the entrance and the exit.

15. The device of claim 14 further comprising a cell delivery system, and wherein the container is a reservoir of the cell delivery system.

16. The device of claim 14 comprising a pump controller to control a speed of movement of the hematopoietic donor cells through the circulation pathway.

17. The device of claim 14 wherein the circulation pathway comprises a tube having an opening being the entrance and a lumen to allow the passage of the hematopoietic donor cells and the fluid, and at least a portion of the lumen includes the surface portion.

18. The device of claim 14 wherein the circulation pathway comprises:

a tube having an opening being the entrance and a lumen to allow the passage of the hematopoietic donor cells and the fluid; and

a chamber connected to the tube, the chamber including an interior wall, at least a portion of the interior wall including the surface portion.

21. The device of claim 5 wherein the expression or activation of PSGL-1, VLA-4 or L-selectin is increased.

22. The device of claim 5 wherein the hematopoietic cells are progenitor cells.

23. A device for treating progenitor donor cells used in cell therapy, comprising:

a surface portion; and

an activation surface including different agents applied to the surface portion, wherein the different agents increase expression or activation of adhesion molecules on progenitor donor cells, the activation surface having ridges configured to promote interaction between the different agents and the progenitor donor cells as the progenitor donor cells contact the activation surface, wherein the activation surface comprises a plurality of activation surface regions each including one or more of the different agents, and wherein the activation surface regions are arranged to allow the progenitor donor cells to contact each of the activation surface regions with the different agents in a predetermined order to allow multiple steps of activation according to a predetermined activation sequence selected so as to increase expression or activated adhesion molecules including LFA-1 or Mac-1 on the progenitor donor cells.